The link between benign prostatic hyperplasia and prostate cancer.
about
Towards engineering hormone-binding globulins as drug delivery agentsP21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human ProstatemPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia.Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.BPH and prostate cancer risk.Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.An introduction to acinar pressures in BPH and prostate cancer.Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.Inflammation and prostate cancer: friends or foe?Testosterone Replacement Therapy on the Natural History of Prostate Disease.Widespread telomere instability in prostatic lesions.Proliferation of Prostate Stromal Cell Induced by Benign Prostatic Hyperplasia Epithelial Cell Stimulated With Trichomonas vaginalis via Crosstalk With Mast Cell.Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate.Prostate cancer outcomes for men who present with symptoms at diagnosis.Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864.Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.Association of Polymorphisms in the VDR, CYP17 and SRD5A2 Genes and Prostate Cancer Among Lebanese MenPromoter Polymorphism (rs12770170, -184C/T) of Microseminoprotein, Beta as a Risk Factor for Benign Prostatic Hyperplasia in Korean Population.Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancerThe cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction.The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle.Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace α1 -Adrenergic Tension in the Human Prostate.27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells.Familial Risks Between Urolithiasis and Cancer.Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate.BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005.Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate.Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases.Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.
P2860
Q28545213-E9AE0692-7D74-42B5-8178-EAAA313D177AQ28551296-0FB8EB87-3B44-42A5-8BA1-05932D61C139Q35921941-51A62119-1F13-4646-BDB8-66278B3D89F9Q35946332-8BC6B7A1-6131-4F09-BF8A-A36AE4D1B5E6Q36891781-82AA7B4B-A117-45FA-A24B-B838513F8029Q37707775-9FF73240-73C7-47AA-8853-55202F096F34Q38105608-379C7D7C-3F63-4CCE-B84C-A518995542D6Q38106624-54EB5612-0935-4D11-8C13-DA09C8B5FEE0Q38207592-CF8219CF-479C-4769-BB42-8DE407D18AACQ38383521-1960A5B1-F613-4614-9D63-CE5E2CC1111CQ38528388-C91E42FA-9B45-4EC0-AA4D-28817F3E1AD0Q38881676-61E44180-05F8-41B3-8531-700A66A49F99Q39136758-2B410BE2-2E13-4E54-A75C-A6FD6877A0FFQ39154967-D8EDCEFF-575C-47F5-A3F8-A09792AD5249Q39526823-32DDF1F6-B4AB-474C-A16B-69128CFF17E9Q40920822-CEA47973-7F7A-4466-A167-C4E840FEAE0DQ40921290-3F0B3F85-8506-473C-A2A8-186323CCD843Q41461592-6B2DA7D1-1CB3-4B84-9BDD-06E8662F3125Q41539781-A9AAC10B-4B5F-4C47-B835-FE0A4FBE08ABQ42409837-EADEB215-E753-4883-9270-FF7938763F3EQ43090975-43C21047-EF9D-48A4-9183-7BAD93283DA0Q44546106-1AD00022-3F5E-460A-A42B-4F502D4742A7Q47098074-FE25C551-1D30-4E5E-B1C1-3F32A794A1E1Q47570403-08DB693E-BCE7-4633-A20C-0EBA7EFEC880Q47997829-2707D045-A87C-4975-9C18-F58570A54252Q48067038-099FFC23-97F7-4B36-8027-B6AE1B4892DBQ49958973-7E28F217-347C-4068-89E1-E9DE4AD824F7Q50267774-2DFD62A4-F51E-4838-A05A-DC3A7C81E744Q50942062-22E8ED9D-F28A-42E0-A5CB-7D2BF296641BQ51640625-673069DD-1754-43DD-8805-172A00C169ECQ52634022-F3CB9EDD-7571-4053-8840-045FFB0E5290Q53106730-C6C0CE65-1B14-4BF5-9325-B6E86F4DEAF0Q55361601-D391D056-237E-4030-B2B3-AFF63DAF10AFQ55515702-B9B49507-8E0E-4753-845A-BAE1900A7556
P2860
The link between benign prostatic hyperplasia and prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The link between benign prostatic hyperplasia and prostate cancer.
@en
type
label
The link between benign prostatic hyperplasia and prostate cancer.
@en
prefLabel
The link between benign prostatic hyperplasia and prostate cancer.
@en
P2860
P356
P1476
The link between benign prostatic hyperplasia and prostate cancer.
@en
P2093
David D Ørsted
Stig E Bojesen
P2860
P2888
P356
10.1038/NRUROL.2012.192
P407
P577
2012-11-20T00:00:00Z
P6179
1022328745